ABSTRACT. Medulloblastoma is a rare brain tumor usually occurring in late childhood or early adolescence. Little is known regarding the cell of origin or cellular events leading to its malignant transformation. We have studied the expression of developmentally regulated mRNA in tumor samples by the Northern hybridization assay to determine a relative stage at which a block to further differentiation occurs. In a series of five medulloblastoma tumors analyzed, only one of eight markers for cellular differentiation, the glial fibrillary acidic protein mRNA, was expressed at significant levels. Interestingly, three of six medulloblastoma tumor samples were found to have elevated levels of c-myc mRNA. In one of these tumors, we have found evidence of mutation of the c-myc protooncogene. We discuss possible mechanisms of c-myc activation in medulloblastoma tumors. (Pediatr Res 28: 63-68, 1990)
Medulloblastoma brain tumors occur primarily in the pediatric population with 80% of all cases diagnosed before age 15 y (1). The cell of origin remains unknown, although some workers (2) suggest that the tumor arises from external granule cells, which are known to undergo postnatal mitosis and migration before their final differentiation. Although the tumor is statistically rare, it is the single most common brain tumor occurring in childhood (1). Despite significant improvements in multimodality therapy, including aggressive neurosurgical techniques, multiagent chemotherapy, and radiation therapy, only approximately 50% of children with this disease are cured (3). Within this group, there is a high incidence of serious neurologic sequelae.
Recently, molecular events have been described that may contribute to the development of CNS tumors. For example, the serum growth factor PDGF, which is the protein product of the cellular gene c-sis, has been found to be secreted by iV-ethyl-iVnitrosourea-induced glial brain tumors (4). Similarly, Liberman et al. (5) have reported amplification, enhanced expression, and possible rearrangement of the c-erbB gene in glial brain tumors. Of more specific interest to medulloblastomas, tumors of neural origin (2), is the family of myc genes. The oncogene N-myc was Received June 30, 1989; accepted March 2, 1990 first described (6) in tumor tissue arising from the peripheral nervous system, i.e. neuroblastomas. Evidence presented in this work links overexpression of the related protooncogene c-myc to medulloblastomas, tumors that arise from the CNS. Although the precise function of the c-myc gene product, a nuclear phosphoprotein (7), has not been defined, expression of the myc family may play a role in making cells competent to respond to signals that induce differentiation or proliferation (8). Enhanced c-myc gene expression has been found in a variety of tumors and cell lines (9-12), which favors a link between c-myc expression and cellular proliferation. Several studies also support a role for c-myc in blocking differentiation. Constitutive expression of cmyc can block mouse erythroleukemia cell (13) and PC 12 pheochromocytoma cell (14) differentiation in vitro and maintain the proliferative state of these cells in the presence of differentiation inducers.
In our report, we have assayed for molecular evidence of the extent of differentiation of five medulloblastoma tumors to identify a relative stage at which differentiation is blocked. mRNA isolated from tumor samples was screened with a panel of radiolabeled cDNA probes. These cDNA probes were selected on the basis that they correspond to functions expressed within the CNS at different stages of neuronal or glial development. From our panel of cDNA probes, only that for GFAP, an intermediate filament protein, was expressed at levels detectable by Northern assay in the tumor RNA. In three of six medulloblastoma tumors analyzed for c-myc expression, we found elevated levels of c-myc mRNA. Moreover, we found that GFAP mRNA expression appeared to be inversely correlated with cmyc mRNA levels in six of six informative tumors.
MATERIALS AND METHODS
Tissue samples. After approval by the Institutional Review Board of the New York University Medical Center, tumor samples were collected directly from the operating room and placed immediately in liquid nitrogen.
DNA probes. The following cDNA probes were used in this study: pGmycScrFl, a 72-bp subclone spanning the 3' end of the human c-myc 1st exon; pmycX-Pstl, a 1.1-kb human c-myc subclone that includes 133 bp of the 5' end of the 2nd exon; and pmyc 413-R/C, a 1.3-kb human c-myc 3rd exon subclone. The c-myc probes were kindly provided by Ethel Cesarman and Riccardo Dalla-Favera (15). A 1-kb N-myc subclone, pNb-1, was obtained from the American Type Culture Collections, Rockville, MD (41011). NF68 a 1.2-kb subclone of the murine 68 000 mol wt neurofilament protein, was kindly provided by Lewis and Cowan (16) . Plasmid Gl, a 2.5-kb mouse subclone of GFAP was also provided by S.A. Lewis and N.J. Cowan (17). pSPT, a 1.8-kb subclone of bovine chromogranin A, was kindly provided by M. L. Grimes (18). Int-lE5, a 520-bp subclone of mouse int-l, was kindly provided by D. G. Wilkinson (19 
RESULTS
Three of six medulloblastoma tumors analyzed have elevated c-myc expression. Initially, a series of seven pediatric tumors was examined for expression of genes that are indicative of differentiation and that are known to be express4 in celIs of neuroectodermal origin. The tumors included five rnedulloblastomas, one ependymoma, and one neuroblastoma; a 4th medulIoblastoma specimen was collected later in the study. Using the selected cDNA probes, Northern analysis from these tumors indicated that only GFAP was expressed at detectable levels (Fig. 1, panel  a, lanes 5-8) . To assess the potential involvement of the ~p n y c protooncogene, we repeated the Northern blots with pmyc 4 13-RJC, a cDNA that spans the 3rd exon of c-myc (Fig. 1, panel b) .
Two medulloblastomas (M-2 and M-3, Fig. 1 , lanes 5 and 6 ) and the neuroblastoma (lane 10) were found to express high levels of c-myc mRNA when compared with adult rat brain and human fetal brain. In each case, the mRNA comigrated with cmyc mRNA from HeLa cells, which are wild type in size. A comparison of band intensities in Figure I , panels a and b, indicatw an inverse correlation between GFAP expression and c-myc expression in the tumor samples analyzed in Figure 1 , lanes 5 through 10.
To control for any possible differences in the quantity of cellular RNA added to each lane, we analyzed by Northern assay the level of @-actin mRNA, which is relatively constant in different samples of similar tissue. The same Northern blot, containing RNA from the original five medulloblastoma tumors plus one additiona1 medulloblastoma, was then stripped and exposed to the radiolabeled human c-myc probe, pmyc 4 13-R/C (Fig. 2,   panel To confirm the results of the Northern blot assay and to investigate possible mechanisms of transcriptional deregulation, we examined the tumor C-myc MRNA by means of the ribonuclease protection assay. Identical aliquots of total cellular RNA from the six rnedulloblastomas in Figure 2 were hybridized with a radiolabeled antisense transcript of mycX-PstI, which overlaps the junction of the 5' end of the 2nd exon and the 1st intron of human Gmyc (Fig. 31 , digested with nuclease, and analyzed by gel electrophoresis. In Figure 3 , protected fragments consistent with elevated ~m y c mRNA expression in tumors M-2, M-3, and M-6 were observed. The size of these bands was the same as obtained with H e h c-myc mRNA, which is wild type in splicing, indicating that the tumor RNA were correctly spliced at the 2nd exon 5' boundary, and that intron sequences are absent from the mRNA. This observation argues against aberrant initiation
